Ontuxizumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Ontuxizumab[1] is a humanized rabbit monoclonal antibody[2] designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).[3]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Chimeric/humanized hybrid (mouse/human) |
| Target | TEM1 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| Chemical and physical data | |
| Formula | C6532H10050N1726O2054S44 |
| Molar mass | 147034.92 g·mol−1 |
Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.[4]
This drug was developed by Morphotek and Ludwig Institute for Cancer Research.[4]
